News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thrasos Therapeutics Appoints Gaétan Gravel And Joseph Zakrzewski To Board Of Directors



8/12/2014 8:20:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTREAL--(BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced that Gaétan Gravel, Life Sciences Portfolio Director at the Fonds de solidarité FTQ, and Joseph (Joe) Zakrzewski have been appointed to the company’s Board of Directors. Mr. Gravel and Mr. Zakrzewski join existing directors Jonathan Wener, Chairman & CEO, Canderel; Dr. Jens Eckstein, President, SR One (corporate venture capital arm of GlaxoSmithKline); Jean George, General Partner, Advanced Technology Ventures; Daniel Hetu, Managing Partner, Lumira Capital; and Richard Andrews, President and CEO, Thrasos Therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES